Colin C. Pritchard,Joaquı́n Mateo,Michael F. Walsh,Navonil De Sarkar,Wassim Abida,Himisha Beltran,Andrea Garofalo,Roman Gulati,Suzanne Carreira,Rosalind A. Eeles,Olivier Elemento,Mark A. Rubin,Dan R. Robinson,Robert J. Lonigro,Maha Hussain,Arul M. Chinnaiyan,Jake Vinson,Julie Filipenko,Levi A. Garraway,Mary‐Ellen Taplin
Inherited mutations in DNA-repair genes such as BRCA2 are associated with increased risks of lethal prostate cancer. Although the prevalence of germline mutations in DNA-repair genes among men with localized prostate cancer who are unselected for family predisposition is insufficient to warrant routine testing, the frequency of such mutations in patients with metastatic prostate cancer has not been established.